Treatment Studies

Research studies help us to advance our knowledge of ADHD and other behavioral disorders. Participating in clinical trials is a great way to access new and cutting-edge treatment

Please contact us at (310) 825-3735 or adhdandmood@ucla.edu if you are interested or know someone who may be interested in participating. More information about our current and past treatment studies can be found below.

All treatment is provided at no cost.

Innovative Non-Medication Treatment Study for ADHD
STATUS	ACTIVE AND SEEKING PARTICIPANTS
AGE	7 - 12 years of age
ELIGIBILITY	Diagnosed with ADHD or has symptoms of inattention, hyperactivity, or impulsivity
STUDY LENGTH	4 - 8 weeks, possible extension
STUDY DETAILS	Participants will receive a comprehensive ADHD evaluation, EEGs, weekly questionnaires, and a novel medical treatment For this innovative treatment, mild electrical signals are used to stimulate the brain during sleep in order to improve behaviors associated with ADHD
FLYER	For more information, please view our study flyer here.
PUBLICATIONS	The details and results of our previous TNS research studies can be found here: An Eight-week, Open-trial, Pilot Feasibility Study of Trigeminal Nerve Stimulation in Youth With Attention-deficit/Hyperactivity Disorder Double-Blind, Sham-Controlled, Pilot Study of Trigeminal Nerve Stimulation for Attention-Deficit/Hyperactivity Disorder
PRINCIPAL INVESTIGATOR: Dr. James McGough

Flash Light Therapy and CBT for ADHD Study
STATUS	ACTIVE AND SEEKING PARTICIPANTS
AGE	14 - 17 years of age
ELIGIBILITY	Diagnosed with ADHD Delayed Sleep-Wake Schedule
STUDY LENGTH	7 weeks
STUDY DETAILS	Participants will receive 2 weeks of flashed light therapy and 4 weeks of cognitive behavioral therapy and at-home flashed light therapy 7 weeks of continuous sleep monitoring with watch and sleep diary
FLYER	For more information, please view our study flyer here.
PRINCIPAL INVESTIGATOR: Dr. Emily Ricketts

Treatment Study for Children and Adolescents with Irritability and Restlessness
STATUS	COMPLETE - NOT SEEKING PARTICIPANTS
AGE	7 - 17 years of age
ELIGIBILITY	Is frequently moody, irritable, cranky, agitated, or distractible Participants must not be diagnosed with autism or Asperger’s disorder.
STUDY LENGTH	12 visits over 3 months
STUDY DETAILS	Participants will receive a comprehensive evaluation and be given an ADHD medication and antidepressant (Fluoxetine) or a placebo The study also includes psychological and laboratory testing, interviews, and weekly questionnaires
FLYER	For more information, please view our study flyer here.
PRINCIPAL INVESTIGATOR: Dr. James McGough

Treatment for Adolescents with Attention-Deficit/Hyperactivity Disorder
STATUS	COMPLETE - NOT SEEKING PARTICIPANTS
AGE	12 - 17 years of age
ELIGIBILITY	Diagnosed with ADHD or has symptoms of inattention, hyperactivity, or impulsivity
STUDY LENGTH	Weekly visits for up to 7 weeks
STUDY DETAILS	Participants will receive a comprehensive evaluation and be given an ADHD medication (methylphenidate) or placebo This study also includes psychological measures and laboratory testing, and weekly questionnaires and interviews
PRINCIPAL INVESTIGATOR: Dr. James McGough

Translational Research to Enhance Cognitive Control (TRECC)
STATUS	COMPLETE - NOT SEEKING PARTICIPANTS
STUDY DETAILS	The purpose of TRECC was to compare the effectiveness of Guanfacine, Focalin XR, and combination treatment with the two on ADHD symptoms. Through the study, a better understanding of the relations between genetic, physiological and psychological processes in children with ADHD was gained. Thus far, TRECC investigators have published electroencephalogram (EEG) findings from TRECC that focus on how differences in the brain contribute to differences among children diagnosed with ADHD. Read more below!
PUBLICATIONS	Characterization of the Theta to Beta Ratio in ADHD: Identifying Potential Sources of Heterogeneity
PRINCIPAL INVESTIGATOR: Dr. James McGough

Preschoolers with ADHD Treatment Studies (PATS)
STATUS	COMPLETE - NOT SEEKING PARTICIPANTS
STUDY DETAILS	The PATS study aimed to measure the safety and efficacy of immediate-release methylphenidate (MPH-IR) in pre-school children (ages 3-5.5 yrs) diagnosed with ADHD. This study determined that MPH-IR is a safe and effective treatment that can be used to improve ADHD symptoms in pre-school children diagnosed with ADHD. In addition, preschoolers with ADHD continue to benefit from treatment with a stimulant medication. Find out more about the study details and results in the articles below.
PUBLICATIONS	Rationale, Design, and Methods of the Preschool ADHD Treatment Study (PATS) Efficacy and Safety of Immediate-Release Methylphenidate Treatment for Preschoolers With ADHD Effectiveness of Methylphenidate in the 10-Month Continuation Phase of the Preschoolers with ADHD Treatment Study (PATS)
PRINCIPAL INVESTIGATOR: Dr. James McGough

ADHD Genetics
STATUS	COMPLETE - NOT SEEKING PARTICIPANTS
STUDY DETAILS	The ADHD genetics study demonstrated that specific variations in one location on the genome (specifically DRD4 and chromosome 16p13) may contribute to the risk for ADHD, specifically ADHD inattentive type.
PUBLICATIONS	Evidence for linkage of a tandem duplication polymorphism up- stream of the dopamine D4 receptor gene (DRD4) with attention deficit hyperactivity disorder (ADHD) Genetic Linkage of Attention-Deficit/Hyperactivity Disorder on Chromosome 16p13, in a Region Implicated in Autism
PRINCIPAL INVESTIGATOR: Dr. James McGough

mcgough2019_tns_adhd_jaacap.pdf

flyer_flashed_light_therapy_and_cbt_for_adhd.pdf